Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Articles|May 9, 2022
Daily Medication Pearl: Mitomycin (Jelmyto)
Author(s)Saro Arakelians, PharmD
Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.
Advertisement
Medication Pearl of the Day: Mitomycin (Jelmyto)
Indication: Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.
Insight:
- Dosing: Administer 1.3 g of sodium bicarbonate orally the evening prior to, the morning of, and 30 minutes prior to instillation procedure.
- Dosage forms: Two 40 mg (each) single-dose vials of mitomycin for pyelocalyceal solution.
- Adverse events: The most common adverse reactions (≥ 20%) are ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting.
- Mechanism of action: Mitomycin inhibits the synthesis of DNA. The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
- Manufacturer: UroGen Pharma
Source:
Advertisement
Related to this article
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5